skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic

Abstract

Although a live attenuated HIV vaccine is not currently considered for safety reasons, a strategy inducing both T cells and neutralizing antibodies to native assembled HIV-1 particles expressed by a replicating virus might mimic the advantageous characteristics of live attenuated vaccine. To this aim, we generated a live attenuated recombinant measles vaccine expressing HIV-1 Gag virus-like particles (VLPs) covered with gp160DELTAV1V2 Env protein. The measles-HIV virus replicated efficiently in cell culture and induced the intense budding of HIV particles covered with Env. In mice sensitive to MV infection, this recombinant vaccine stimulated high levels of cellular and humoral immunity to both MV and HIV with neutralizing activity. The measles-HIV virus infected human professional antigen-presenting cells, such as dendritic cells and B cells, and induced efficient presentation of HIV-1 epitopes and subsequent activation of human HIV-1 Gag-specific T cell clones. This candidate vaccine will be next tested in non-human primates. As a pediatric vaccine, it might protect children and adolescents simultaneously from measles and HIV.

Authors:
 [1];  [2]; ; ; ;  [1];  [3]; ;  [2];  [1]
  1. Laboratoire de Genomique Virale et Vaccination, CNRS URA 3015, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15 (France)
  2. Unite Virus et Immunite, CNRS URA 3015, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris Cedex 15 (France)
  3. Plateforme de Microscopie Ultrastructurale, Institut Pasteur, 25 rue du Dr. Roux, 75724 Paris Cedex 15 (France)
Publication Date:
OSTI Identifier:
21357515
Resource Type:
Journal Article
Journal Name:
Virology
Additional Journal Information:
Journal Volume: 388; Journal Issue: 1; Other Information: DOI: 10.1016/j.virol.2009.02.047; PII: S0042-6822(09)00159-7; Copyright (c) 2009 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Journal ID: ISSN 0042-6822
Country of Publication:
United States
Language:
English
Subject:
63 RADIATION, THERMAL, AND OTHER ENVIRONMENTAL POLLUTANT EFFECTS ON LIVING ORGANISMS AND BIOLOGICAL MATERIALS; AIDS VIRUS; ANTIBODIES; ANTIGENS; CELL CULTURES; IMMUNITY; MEASLES; MICE; VACCINES; ANIMALS; DISEASES; INFECTIOUS DISEASES; MAMMALS; MICROORGANISMS; PARASITES; RODENTS; VERTEBRATES; VIRAL DISEASES; VIRUSES

Citation Formats

Guerbois, Mathilde, Moris, Arnaud, Combredet, Chantal, Najburg, Valerie, Ruffie, Claude, Fevrier, Michele, Cayet, Nadege, Brandler, Samantha, Schwartz, Olivier, and Tangy, Frederic. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic. United States: N. p., 2009. Web. doi:10.1016/j.virol.2009.02.047.
Guerbois, Mathilde, Moris, Arnaud, Combredet, Chantal, Najburg, Valerie, Ruffie, Claude, Fevrier, Michele, Cayet, Nadege, Brandler, Samantha, Schwartz, Olivier, & Tangy, Frederic. Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic. United States. doi:10.1016/j.virol.2009.02.047.
Guerbois, Mathilde, Moris, Arnaud, Combredet, Chantal, Najburg, Valerie, Ruffie, Claude, Fevrier, Michele, Cayet, Nadege, Brandler, Samantha, Schwartz, Olivier, and Tangy, Frederic. Mon . "Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic". United States. doi:10.1016/j.virol.2009.02.047.
@article{osti_21357515,
title = {Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DELTAV1V2 is strongly immunogenic},
author = {Guerbois, Mathilde and Moris, Arnaud and Combredet, Chantal and Najburg, Valerie and Ruffie, Claude and Fevrier, Michele and Cayet, Nadege and Brandler, Samantha and Schwartz, Olivier and Tangy, Frederic},
abstractNote = {Although a live attenuated HIV vaccine is not currently considered for safety reasons, a strategy inducing both T cells and neutralizing antibodies to native assembled HIV-1 particles expressed by a replicating virus might mimic the advantageous characteristics of live attenuated vaccine. To this aim, we generated a live attenuated recombinant measles vaccine expressing HIV-1 Gag virus-like particles (VLPs) covered with gp160DELTAV1V2 Env protein. The measles-HIV virus replicated efficiently in cell culture and induced the intense budding of HIV particles covered with Env. In mice sensitive to MV infection, this recombinant vaccine stimulated high levels of cellular and humoral immunity to both MV and HIV with neutralizing activity. The measles-HIV virus infected human professional antigen-presenting cells, such as dendritic cells and B cells, and induced efficient presentation of HIV-1 epitopes and subsequent activation of human HIV-1 Gag-specific T cell clones. This candidate vaccine will be next tested in non-human primates. As a pediatric vaccine, it might protect children and adolescents simultaneously from measles and HIV.},
doi = {10.1016/j.virol.2009.02.047},
journal = {Virology},
issn = {0042-6822},
number = 1,
volume = 388,
place = {United States},
year = {2009},
month = {5}
}